Scientists at Johns Hopkins Medicine have grown miniature brain models from the cells of Alzheimer's patients and used them to study how different people respond to the same medication. The results point toward a future where treatment decisions could be guided by a patient's own biology before a drug is ever prescribed.
The research, reported by Johns Hopkins Medicine and published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, focused on lab-grown tissues called organoids. These are small clusters of human brain cells, cultivated in a dish, that mimic some of the structure and behavior of real brain tissue.
Alzheimer's disease affects more than 7 million Americans and remains incurable. Many patients develop neuropsychiatric symptoms, including anxiety, depression, and agitation. Doctors often prescribe selective serotonin reuptake inhibitors, or SSRIs, to manage these symptoms, but responses to the drugs vary widely from patient to patient. The Johns Hopkins team wanted to know whether organoids could reveal why.
The researchers started with blood samples collected from Alzheimer's patients at the NIH-funded Johns Hopkins Alzheimer's Disease Research Center. They reprogrammed those blood cells into a stem cell-like state, then guided them to develop into miniature models of the hindbrain, a region at the back of the skull that helps control breathing, sleep, and heart rate. They then exposed the organoids to escitalopram oxalate, a common SSRI, and tracked what happened.
The organoids showed striking differences in how they responded to the drug, depending on which patient's cells they came from. That variability mirrored the real-world pattern doctors see when prescribing the same medication to different patients.
Study leader Vasiliki Machairaki, associate professor of genetic medicine at the Johns Hopkins University School of Medicine, described the broader potential. "Our study suggests that large-scale, patient-derived brain organoids and the vesicles they secrete can help us stage Alzheimer's disease, investigate the mechanisms that drive it and assess how patient subgroups may respond to different treatments."
The vesicles she referenced are tiny particles called extracellular vesicles that the organoids release naturally. The team found that these particles carry cellular information and may eventually serve as biomarkers, helping doctors determine not only whether a patient has Alzheimer's but how far the disease has progressed. That would be a meaningful advance in a field where staging the disease accurately remains difficult.
The research received partial funding from the National Institutes of Health. The study does not claim that organoid testing is ready for clinical use, but the findings add to a growing body of evidence that patient-derived brain models could reshape how Alzheimer's treatments are developed and selected.
